LEADER 01038nam0 22002411i 450 001 UON00227877 005 20231205103445.642 100 $a20030730d2000 |0itac50 ba 101 $agre 102 $aGR 105 $a|||| 1|||| 200 1 $aˆOi ‰Ellenes Orthodoxoi eis ten Kampanian tes Italias apo tes Aloseos mechri tes enoseos tis Italias kai tou Nkaribalde$fGennadiou Zerbou 210 $aBenetia$c[s.e]$d2000 215 $a328 p.$d24 cm. 606 $aChiesa ortodossa greca$xItalia$3UONC043370$2FI 620 $aIT$dVenezia$3UONL000039 700 1$aZERBOS$bGennadios$3UONV138085$0686840 801 $aIT$bSOL$c20250808$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00227877 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI E 0153 $eSI EO 33325 5 0153 996 $aEllenes Orthodoxoi eis ten Kampanian tes Italias apo tes Aloseos mechri tes enoseos tis Italias kai tou Nkaribalde$91271668 997 $aUNIOR LEADER 03689nam 2200421z- 450 001 9910346756603321 005 20210211 035 $a(CKB)4920000000094148 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/55785 035 $a(oapen)doab55785 035 $a(EXLCZ)994920000000094148 100 $a20202102d2018 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPathogenic Advances and Therapeutic Perspectives for Eosinophilic Inflammation 210 $cFrontiers Media SA$d2018 215 $a1 online resource (279 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88945-624-2 330 $aWith the recent approval of the first eosinophil-depleting therapeutic agents targeting the IL-5 pathway for treatment of severe eosinophilic asthma, eosinophils and eosinophilic disorders are in the limelight. Indeed, setbacks during clinical development of these compounds have revealed how much remains to be known about eosinophil biology in vivo, and have nurtured profuse research both on basic eosinophil biology and on pathogenic disease mechanisms, in order to better delineate the most meaningful targets for innovative therapeutic strategies. On one hand, variable degrees of eosinophil depletion observed in some compartments during IL-5-targeted treatment indicate that certain eosinophil subsets may not rely on this cytokine and/or that other important pro-eosinophilic mediators and signaling pathways are operative in vivo. On the other hand, it is increasingly clear that disorders involving eosinophils such as asthma are the final outcome of complex interactions between diverse cell types and mediators, beyond eosinophils and IL-5. These include type 2 helper T (Th2) cells and innate lymphoid cells, mast cells, and a variety of factors that either activate eosinophils or are released by them. Although a considerable amount of research has focused on asthma because it is a common condition and because management of severe asthma remains a major challenge, several rare eosinophilic disorders with more homogenous features have proven to be extremely useful models to reach a better understanding of the involvement of eosinophils in tissue damage and dysfunction, and of the micro-environmental interactions operating within the complex network of eosinophilic inflammation. Unraveling this interplay has resulted in advances in the development of molecular tools to detect disease subsets and to monitor therapeutic responses, and in identification of promising new therapeutic targets. This Research Topic dedicated to eosinophilic conditions covers aspects of the biology of eosinophils and closely related cells of particular relevance for drug development, reports on translational research investigating pathogenic mechanisms of specific eosinophilic disorders in humans that will likely result in significant changes in the way patients are managed, and presents an overview of the current advancement of targeted drug development for these conditions, with a special focus on asthma. 606 $aMedicine$2bicssc 610 $aAsthma 610 $aEosinophil Biology 610 $aEosinophilic Esophagitis 610 $aHypereosinophilic Syndrome 610 $aILC2 610 $amast cell 610 $aTh2 cell 615 7$aMedicine 700 $aFlorence E. Roufosse$4auth$01296324 702 $aMats W. Johansson$4auth 906 $aBOOK 912 $a9910346756603321 996 $aPathogenic Advances and Therapeutic Perspectives for Eosinophilic Inflammation$93024001 997 $aUNINA